Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
LONDON - TheraCryf plc (AIM:TCF), a clinical stage drug development company focusing on neuropsychiatry and oncology, announced Monday that it has posted its Annual Report and Accounts for the year ended March 31, 2025, to shareholders.
The company will hold its Annual General Meeting on Wednesday, July 9, 2025, at 2:30 p.m. at the Royal Society of Medicine in London. Following the AGM, the management team will host an in-person presentation to discuss full-year results and recent progress with the company’s Orexin antagonist program.
TheraCryf develops treatments for brain disorders including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company’s business model involves generating data to reach preclinical or clinical proof of concept before partnering its clinical programs with pharmaceutical companies for larger trials and commercialization.
The company maintains collaborations with several academic institutions, including the University of Manchester, La Sapienza University of Rome, Erasmus Medical (TASE:BLWV) Center in Rotterdam, Kings College London, and the University of Michigan.
TheraCryf is headquartered at Alderley Park in Cheshire, UK, and is listed on London’s AIM market.
The information in this article is based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.